[{"id":"41c64d00-75dd-4fa2-9ce1-9e342496ddc1","acronym":"ELAINE 1","url":"https://clinicaltrials.gov/study/NCT03781063","created_at":"2021-01-18T18:42:03.161Z","updated_at":"2024-07-02T16:35:08.944Z","phase":"Phase 2","brief_title":"Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","source_id_and_acronym":"NCT03781063 - ELAINE 1","lead_sponsor":"Sermonix Pharmaceuticals Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Fablyn (lasofoxifene)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/20/2019","start_date":" 09/20/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-18"},{"id":"fab65276-bb46-4e33-bd0f-2cadd6a74b15","acronym":"","url":"https://clinicaltrials.gov/study/NCT04256941","created_at":"2021-01-18T20:41:27.231Z","updated_at":"2024-07-02T16:35:09.598Z","phase":"Phase 2","brief_title":"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study","source_id_and_acronym":"NCT04256941","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • ER mutation • ER Y537S • ER D538G • ESR1 mutation","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • ER mutation • ER Y537S • ER D538G • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 05/31/2019","start_date":" 05/31/2019","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 09/22/2023","study_completion_date":" 09/22/2023","last_update_posted":"2024-04-16"},{"id":"2f8a360e-0756-4c29-9da9-648e54e67f50","acronym":"H3B-6545-A001-101","url":"https://clinicaltrials.gov/study/NCT03250676","created_at":"2021-01-17T17:33:34.840Z","updated_at":"2024-07-02T16:35:25.240Z","phase":"Phase 1/2","brief_title":"Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03250676 - H3B-6545-A001-101","lead_sponsor":"Eisai Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER Y537S • ER D538G • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER Y537S • ER D538G • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e H3B-6545"],"overall_status":"Completed","enrollment":" Enrollment 206","initiation":"Initiation: 08/17/2017","start_date":" 08/17/2017","primary_txt":" Primary completion: 10/26/2023","primary_completion_date":" 10/26/2023","study_txt":" Completion: 10/26/2023","study_completion_date":" 10/26/2023","last_update_posted":"2023-12-25"},{"id":"84de35bd-d435-4d10-9e06-8c241fe78f57","acronym":"","url":"https://clinicaltrials.gov/study/NCT03202862","created_at":"2021-01-18T15:47:35.613Z","updated_at":"2024-07-02T16:37:20.527Z","phase":"Phase 2","brief_title":"The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer","source_id_and_acronym":"NCT03202862","lead_sponsor":"Fudan University","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER Y537C","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER Y537C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2017-06-29"}]